Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer

The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite variable treatment response, no biomarkers exist to stratify patients for cetuximab therapy in HNSCC. Here, we applied unbias...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouhaddou, Mehdi, Lee, Rex H., Li, Hua, Bhola, Neil E., O’Keefe, Rachel A., Naser, Mohammad, Zhu, Tian Ran, Nwachuku, Kelechi, Duvvuri, Umamaheswar, Olshen, Adam B., Roy, Ritu, Hechmer, Aaron, Bolen, Jennifer, Keysar, Stephen B., Jimeno, Antonio, Mills, Gordon B., Vandenberg, Scott, Swaney, Danielle L., Johnson, Daniel E., Krogan, Nevan J., Grandis, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564908/
https://www.ncbi.nlm.nih.gov/pubmed/34546978
http://dx.doi.org/10.1172/jci.insight.151982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564908/
https://www.ncbi.nlm.nih.gov/pubmed/34546978
http://dx.doi.org/10.1172/jci.insight.151982

Ejemplares similares